Spain's pharma industry committed to Big Data to optimize the use of healthcare information

Maximizing the potential offered by big amounts of information within the Spanish healthcare sector, while fostering the evolution of healthcare systems towards value and healthcare outcomes based models.

The latter are the two main objectives of the IMI Big Data for Better Outcomes (BD4BO), of which pharma trade group Farmaindustria is a member alongside pharmaceutical companies, patients’ associations and public institutions.

This program is already being developed in four specific diseases (Alzheimer’s disease, hematological malignancy, multiple sclerosis and cardiovascular diseases), in which research teams participating are able to use Big Data to integrate information which allow to meet the most pressing needs arising from these conditions, developing more efficient treatments while facilitating decision making processes.